BRCA1 and neoplasm: Taken with evidence from clinical trials, which demonstrate no benefit from SERMs in reducing the incidence of ER-negative tumours, this suggests that SERMs are unlikely to be effective chemopreventive agents in BRCA1 mutation carriers (who are more likely to develop ER-negative tumours).